Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Rd
  6. Phase Ii

Phase II

Evaluate

Thumbnail
May 25, 2023

Archer misses the target

Annexon’s failure in geographic atrophy could clear the way for its rivals.

Thumbnail
May 25, 2023

Normal service resumes in amyotrophic lateral sclerosis

Article image
Vantage logo
May 23, 2023

EASC 2023 – Arrowhead takes on Regeneron in cholesterol lowering

Article image
Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

A hit on one goal helps, but future Nash data will be more decisive.

Article image
Vantage logo
May 17, 2023

Roche’s multiple sclerosis win puts more pressure on Sanofi

Article image
Vantage logo
May 17, 2023

Immutep throws its hat into the Lag3 ring

Article image
Vantage logo
May 10, 2023

Boehringer and Zealand take a baby step in obesity

Article image
Vantage logo
May 02, 2023

Pliant’s latest lung disease data fail to convince

Article image
Vantage logo
April 25, 2023

Emerald gleams for Morphic

Ulcerative colitis data promise the efficacy and safety of Entyvio, but in a pill.

Article image
Vantage logo
April 25, 2023

Biogen gears up for a big clearout

Article image
Vantage logo
April 24, 2023

Uveal melanoma gives Ideaya a clear line of sight to market

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up